HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

Background:In metastatic colorectal cancer (mCRC), KRAS is the only validated biomarker used to select patients for administration of epidermal growth factor receptor (EGFR)-targeted therapies. To identify additional predictive markers, we investigated the importance of HER2, the primary EGFR dimerisation partner, in this particular disease.Methods:We evaluated the HER2 gene status by fluorescence in situ hybridisation (FISH) in 170 KRAS wild-type mCRC patients treated with cetuximab or panitumumab.Results:Depending on HER2 gene copy number status, patients showed three distinct cytogenetic profiles: 4% of patients had HER2 gene amplification (R:HER2/CEP17⩾2) in all neoplastic cells (HER2-all-A), 61% of patients had HER2 gain due to polysomy or to gene amplification in minor clones (HER2-FISH+*), and 35% of patients had no or slight HER2 gain (HER2-FISH−). These subgroups were significantly correlated with different clinical behaviours, in terms of response rate (RR; P=0.0006), progression-free survival (PFS; P<0.0001) and overall survival (OS; P<0.0001). Patients with HER2-all-A profile experienced the worst outcome, patients with HER2-FISH− profile showed an intermediate behaviour and patients with HER2-FISH+* profile were related to the highest survival probability (median PFS in months: 2.5 vs 3.9 vs 7.6, respectively; median OS in months: 4.2 vs 9.7 vs 13, respectively).Conclusion:HER2 gene copy number status may influence the clinical response to anti-EGFR-targeted therapy in mCRC patients.

• Publication year

  2013

• Venue

  British Journal of Cancer

• Publication date

  2013-01-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/bjc.2013.4PMID 23348520PMCID 3593567
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mitelman database of chromosome aberrations and gene fusions in cancer

  2014cited by this paper
• Mitelman Database (Chromosome Aberrations and Gene Fusions in Cancer)

  2014cited by this paper
• 急速に進行増大した epidermal growth factor receptor陽性乳腺扁平上皮癌の１例

  2013cited by this paper
• Retrospective EGFR mutation testing of clinical specimens from the EURTAC trial of erlotinib in non-small cell lung cancer (NSCLC) using a novel allele-specific PCR (AS-PCR) assay.

  2012cited by this paper
• Internal Quality Assurance Program for ERBB2 (HER2) Testing Improves the Selection of Breast Cancer Patients for Treatment with Trastuzumab

  2012cited by this paper
• An update on the current and emerging targeted agents in metastatic colorectal cancer.

  2012cited by this paper
• KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice.

  2011influential reference
• EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients

  2011cited by this paper
• Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

  2011cited by this paper
• A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

  2011influential reference
• T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.

  2011cited by this paper
• Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study

  2011cited by this paper
• Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

  2011cited by this paper
• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

  2010cited by this paper
• Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome

  2010cited by this paper
• Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.

  2009cited by this paper
• Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis

  2009cited by this paper
• Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer

  2009cited by this paper
• EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer

  2009cited by this paper
• PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

  2009cited by this paper
• Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

  2008cited by this paper
• EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.

  2008cited by this paper
• Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study

  2008cited by this paper
• An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology

  2008cited by this paper
• Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.

  2007cited by this paper
• Interphase FISH as a new tool in tumor pathology

  2007cited by this paper
• EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

  2007cited by this paper
• PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

  2007influential reference
• Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens

  2007cited by this paper
• HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer

  2006cited by this paper
• Non-small cell lung cancer: Clinical practice guidelines in oncology

  2006cited by this paper
• Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.

  2005influential reference
• Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

  2005cited by this paper
• Epidermal growth factor receptor: mechanisms of activation and signalling.

  2003cited by this paper
• EGF receptor.

  1999cited by this paper
• The teaching of clinical oncology in Italian medical schools. A survey among teachers and students.

  1993cited by this paper
• Epidermal growth factor receptors

  1981cited by this paper

• Tucatinib in the treatment of HER2-overexpressing gastrointestinal cancers: current insights and future prospects

  2025cites this paper
• HER2 alterations across solid tumors: implications for comprehensive testing

  2025cites this paper
• Survival outcomes of ERBB2-amplified metastatic colorectal cancer treated with first-line chemotherapy

  2025cites this paper
• Response to Biologics in Patients With Early-Onset Treatment-Naïve Metastatic Colorectal Cancer—An Aide et Recherche en Cancérologie Digestive Database Analysis

  2025cites this paper
• Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor Approach.

  2025cites this paper
• Combination Therapy of Trastuzumab and Lapatinib in Chemorefractory HER2-Positive Metastatic Colorectal Cancer: An Efficacy and Safety Analysis

  2025cites this paper
• Addressing Challenges in Targeted Therapy for Metastatic Colorectal Cancer

  2025influential citation
• Precision treatment for human epidermal growth factor receptor 2-amplified advanced rectal cancer: A case report

  2025cites this paper
• HER2-targeted therapy in colorectal cancer: a comprehensive review

  2025cites this paper
• HER2-Positive Metastatic Colorectal Cancer

  2024cites this paper
• HER2 targeted therapy in colorectal Cancer: Current landscape and future directions.

  2024cites this paper
• The Evolving Role of Genomics in Colorectal Cancer.

  2024cites this paper
• Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review

  2024cites this paper
• A Comprehensive Review of HER2 in Cancer Biology and Therapeutics

  2024cites this paper
• Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

  2024cites this paper
• HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405

  2024cites this paper
• Molecular profiling of colorectal cancer in a genetically admixed Hispanic population

  2023cites this paper
• The role of negative hyperselection in metastatic colorectal cancer

  2023cites this paper
• Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

  2023cites this paper
• Effect of human epidermal growth factor receptor 2 overexpression in metastatic colorectal cancer on standard chemotherapy outcomes

  2023cites this paper
• Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes

  2023cites this paper
• Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer

  2023cites this paper
• Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements

  2023cites this paper
• Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

  2023cites this paper
• New developments in targeted therapy for metastatic colorectal cancer

  2023cites this paper
• Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies

  2023influential citation
• Clinical Oncogenomics and Personalized Medicine in Colorectal Cancer for the Surgeon: What We Need to Know and What the Future Holds

  2022cites this paper
• Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis

  2022cites this paper
• Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer

  2022cites this paper
• Current concepts of anti-EGFR targeting in metastatic colorectal cancer

  2022cites this paper
• Towards precision oncology with patient-derived xenografts

  2022cites this paper
• Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline

  2022cites this paper
• Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer.

  2022cites this paper
• The HER family as therapeutic targets in colorectal cancer.

  2022cites this paper
• Prognostic and predictive molecular biomarkers in advanced colorectal cancer.

  2022cites this paper
• HER2 targeted therapy in colorectal cancer: New horizons.

  2022cites this paper
• Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations

  2021cites this paper
• Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation.

  2021cites this paper
• Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer

  2021cites this paper
• Precision oncology in metastatic colorectal cancer — from biology to medicine

  2021cites this paper
• Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma

  2021cites this paper
• Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  2021cites this paper
• OTT_A_312820 4087..4098

  2021cites this paper
• Personalizing first-line treatment in advanced colorectal cancer: Present status and future perspectives

  2021cites this paper
• More than FOLFOX and FOLFIRI: The Management of Metastatic Colorectal Cancer in the Era of Precision Oncology

  2021cites this paper
• Colorectal Cancer: From Genetic Landscape to Targeted Therapy

  2021cites this paper
• Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance

  2020cites this paper
• Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer

  2020cites this paper
• Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019

  2020cites this paper
• Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma

  2020cites this paper
• Tumors of the Gastrointestinal System Including the Pancreas

  2020cites this paper
• KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer

  2020cites this paper
• Metastatic Colorectal Cancer: Prognostic And Predictive Factors.

  2020cites this paper
• HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.

  2020cites this paper
• Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements towards Individualizing the Treatment

  2020cites this paper
• Development ofHER2-targeted Therapies for Gastrointestinal Cancer

  2020cites this paper
• Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review

  2020cites this paper
• Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy: A case report

  2020cites this paper
• Clasificación molecular del cáncer colorrectal, su impacto pronóstico y terapéutico: un paso crucial hacia la medicina personalizada

  2020influential citation
• HER2 in Colorectal Carcinoma: Are We There yet?

  2020cites this paper
• Distant Metastasis in Colorectal Cancer Patients—Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review

  2020cites this paper
• Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents

  2019cites this paper
• A practical guide to biomarkers for the evaluation of colorectal cancer

  2019cites this paper
• The Developing Story of Predictive Biomarkers in Colorectal Cancer

  2019cites this paper
• Clinical significance of HER2 and EGFR expression in colorectal cancer patients with ovarian metastasis

  2019cites this paper
• HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer.

  2019cites this paper
• FOLFOXIRI plus biologics in advanced colorectal cancer

  2019cites this paper
• Precision treatment in colorectal cancer: Now and the future

  2019cites this paper
• Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer.

  2019cites this paper
• HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.

  2019cites this paper
• Translational Research in Colorectal Cancer: Current Status and Future Perspectives of Multimodal Treatment Approach

  2019cites this paper
• Biomarker-guided therapy for colorectal cancer: strength in complexity

  2019cites this paper
• The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer.

  2019cites this paper
• KRAS, NRAS, BRAF, HER2 and Microsatellite Instability in Metastatic Colorectal Cancer – Practical Implications for the Clinician

  2019cites this paper
• Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer

  2019cites this paper
• Current and emerging biomarkers in metastatic colorectal cancer.

  2019cites this paper
• Molecular subtypes of colorectal cancer: An emerging therapeutic opportunity for personalized medicine

  2019influential citation
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

  2019cites this paper
• Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives

  2018cites this paper
• Colorectal cancer genomics and designing rational trials.

  2018cites this paper
• Resistance of Colorectal Tumors to Anti-EGFR Antibodies

  2018cites this paper
• Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer

  2018cites this paper
• Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping

  2018cites this paper
• The Role of HER2 Testing in Advanced Colorectal Cancer

  2018cites this paper
• Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.

  2018cites this paper
• Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer

  2018influential citation
• Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases

  2018cites this paper
• Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.

  2018influential citation
• Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting

  2018cites this paper
• Patients with RAS wild-type right-sided unresectable liver-confined mCRC also benefit from cetuximab plus chemotherapy in first-line treatment.

  2018cites this paper
• HER2 Deregulation in Lung Cancer: Right Time to Adopt an Orphan?

  2018cites this paper
• HER2-targeted therapy: an emerging strategy in advanced colorectal cancer

  2018cites this paper
• Preoperative radiomic signature based on multiparametric magnetic resonance imaging for noninvasive evaluation of biological characteristics in rectal cancer

  2018cites this paper
• Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status

  2018cites this paper
• Molecular Markers and Mutational Analysis

  2018cites this paper
• HER2: An emerging target in colorectal cancer.

  2018cites this paper
• The Winding Roadmap of Biomarkers Toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer

  2018cites this paper
• Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie.

  2017cites this paper
• Copy number variations in DCC/18q and ERBB2/17q are associated with disease‐free survival in microsatellite stable colon cancer

  2017cites this paper
• HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild‐type RAS and BRAF

  2017cites this paper